Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes
Sponsor: University of Colorado, Denver
Summary
Kidney disease is a common problem among people with type 1 diabetes and can lead to disability, dialysis, and early death. Inflammation plays a key role in the development of kidney disease in type 1 diabetes and targeting leukotrienes, inflammatory chemicals the body releases in response to allergic reactions, may represent a promising therapy to slow the progression of diabetic kidney disease. The current proposal will investigate whether montelukast, a leukotriene blocker, lowers increased levels of protein in the urine (an early marker of diabetic kidney disease), and improves kidney and cardiovascular function in people with type 1 diabetes and kidney disease.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2023-01-26
Completion Date
2025-10
Last Updated
2025-05-29
Healthy Volunteers
No
Conditions
Interventions
Montelukast
10mg daily
Placebo
1 capsule daily
Locations (1)
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States